Pfiz­er spells out PhI­II ta­la­zoparib da­ta in NE­JM ar­ti­cle; Tolero teams up with Ab­b­Vie for AML com­bo

→ David Hung of­fered a hard sell of his ex­per­i­men­tal PARP drug ta­la­zoparib while bid­ders lined up in what turned out as a $14 bil­lion Medi­va­tion buy­out by Pfiz­er. Now re­searchers are spelling out all the da­ta in an ar­ti­cle in the New Eng­land Jour­nal of Med­i­cine as Pfiz­er lines up a quick re­view and like­ly OK for a drug that will face some well en­trenched com­peti­tors.

→ Salt Lake City-based Tolero Phar­ma­ceu­ti­cals has struck a deal to share the costs on an up­com­ing com­bo can­cer drug tri­al with Ab­b­Vie. Re­searchers will match Tolero’s alvo­cidib, a CDK9 drug, with Ab­b­Vie’s vene­to­clax for treat­ment re­sis­tant cas­es of acute myeloid leukemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER